UNSPSC 51263113: Bucumolol

This classification denotes a beta-adrenergic blocking agent with the molecular formula C17H23NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier U8WVJ3501L, chemically known as 8-(3-((1,1-dimethylethyl)amino)-2-hydroxypropoxy)-5-methyl-2h-1-benzopyran-2-one but generally known as bucumolol, which bears US NIH Compound Identifier 169787. Bucumolol most often comes in base and hydrochloride forms. European Medicines Agency schedules Bucumolol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05954MIG.

UNSPSC 51263113 Bucumolol is a Commodity code that in recent state and local activity covers procurement of naloxone and drug deactivation systems for community health and emergency response programs. The code appears in solicitations from county health departments and state health agencies seeking pharmaceutical products and related systems to support opioid-crisis response and pharmacy-benefit modernization initiatives. Issuing bodies include county governments with community health responsibilities and state health and human services commissions managing pharmacy programs for employee and retiree populations.

Seminole County, Florida issued IFB 60459723LAS in June 2026 to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to its Community Health Building in Sanford, with a response deadline of July 26, 2023. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 seeking vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, with an April 3, 2026 response deadline; this exploratory RFI addresses state-level prescription fulfillment and cost management strategies outside traditional pharmacy benefit manager and group purchasing organization channels. Geographic activity is concentrated in Florida and Texas, with procurement spanning county-level community health initiatives and state-level pharmacy benefit modernization. Recent opportunities show both emergency-response product procurement (naloxone and drug deactivation systems) and strategic pharmacy-program contracting, indicating the code captures both commodity purchasing and higher-order health-system transformation work.